Search

Introduction: Despite substantial advances in the treatment of Hemophilia A with the use of concentrated factor VIII preparations during recent decades, bleeding episodes still occur from time to time. The development of inhibitors significantly reduces the efficacy of traditional replacement therapy, seriously increasing morbidity and mortality in these patients. Emicizumab (HEMLIBRA ®) is a chimeric bispecific humanized antibody that bridges activated FIX and FX and thus restores the function of missing activated FVIII. Aim: The aim of the study was to analyze the literature date of the effect of Emicizumab in the treatment of Hemophilia A. Results: Multicenter randomized studies called HAVEN have shown excellent results of this medication in the treatment of patients with Hemophilia A. FVIII inhibitors do not bind to or neutralize Emicizumab and therefore have no effect on the hemostatic activity of the drug. Emicizumab prophylaxis produced a significant reduction in treated bleedings of 79%, compared to with the group of patients on prophylaxis with bypassing agents, while the rate grew up to even 95% after longer observation. Other studies have also confirmed good treatment results and a favorable safety profile in both adults and children. In the cases of bleeding events or preparation for immediate surgical interventions, it is recommended to user FVII (NovoSeven) ® according to previous guidelines. Conclusion: The results of the prophylactic use of Emicizumabhave so far shown that it may be a revolutionary preparation that can significantly reduce bleeding episodes and improve the quality of life of patients with Hemophilia A. Nevertheless, further testing of this drug is required.

In order to analyze biomineralized microscopic structures on the microscopic level, they must be previously subjected to histological in vitro demineralization process, which removes the inorganic component. The speed of demineralization and the influence on the preservation of tissue morphology are the two most important parameters for the choice of decalcifying solution. The solution of Na2-EDTA (ethylenediaminetetraacetic acid disodium salt), madein different concentrations, is considered to bethe slowest, but alsothe most reliable in means of demineralization. The aim of the study was to investigate the possible acceleration of tooth samples demineralization with alkalinized solution of Na2-EDTA,using different conditions of agitation, as well as periodic renewal of the solution for demineralization. Twelve wisdom teeth were used for the purposes of research, extracted for orthodontic reasons. The process of demineralization was performed in the 18.6% aqueous solution of Na2-EDTA. During 45 days, the decline of the specimen’sweight was measured for three physical conditions: the irradiation of the tooth halves samples in the demineralizing agent with the microwaves was used as an agitating technique, 24-hour stirring of the demineralizing agent with the tooth samples on the magnetic stirrer was applied, and the demineralization of the material on the room temperature. Each of these conditions was further subdivided into two groups: in one the demineralizing agent was constant during 45 days of the experiment, and in the second the demineralizing agent was replaced by the same volume of new solution every three days. Demineralized samples were routinely processed to microscopic slides, stained with hematoxylin and eosin. The preservation of dental structures up to cytological details of different cell types in dental pulp was evidenced on microscopic slides. Demineralization of teeth with alkalinized solution of Na2-EDTA runs independently of examined types of agitation and/or renewal of chelating solution. It is possible to make a significant laboratory rationalization for in vitro tissue demineralization by excluding physical agitation, and frequent renewal of demineralizing solution. Acta Medica Medianae 2015;54(4):24-31.